Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Dhadda, S"" wg kryterium: Wszystkie pola


Tytuł:
Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Autorzy:
Swanson CJ; Eisai Inc., Woodcliff Lake, NJ, USA.
Zhang Y; Eisai Inc., Woodcliff Lake, NJ, USA.
Dhadda S; Eisai Inc., Woodcliff Lake, NJ, USA.
Wang J; Eisai Inc., Woodcliff Lake, NJ, USA.
Kaplow J; Eisai Inc., Woodcliff Lake, NJ, USA.
Lai RYK; Eisai Ltd., Hatfield, UK.
Lannfelt L; BioArctic AB, Warfvinges väg 35, SE-112 51, Stockholm, Sweden.; Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden.
Bradley H; Eisai Inc., Woodcliff Lake, NJ, USA.
Rabe M; Eisai Inc., Woodcliff Lake, NJ, USA.
Koyama A; Eisai Inc., Woodcliff Lake, NJ, USA.
Reyderman L; Eisai Inc., Woodcliff Lake, NJ, USA.
Berry DA; Berry Consultants, LLC, Austin, TX, USA.
Berry S; Berry Consultants, LLC, Austin, TX, USA.
Gordon R; Eisai Ltd., Hatfield, UK.
Kramer LD; Eisai Inc., Woodcliff Lake, NJ, USA.
Cummings JL; Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA. .
Pokaż więcej
Źródło:
Alzheimer's research & therapy [Alzheimers Res Ther] 2022 May 21; Vol. 14 (1), pp. 70. Date of Electronic Publication: 2022 May 21.
Typ publikacji:
Published Erratum
Tytuł:
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
Autorzy:
McDade E; The DIAN-TU, Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Cummings JL; Chambers-Grundy Center for Transformative Neuroscience, Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA.
Dhadda S; Eisai Inc., Nutley, NJ, USA.
Swanson CJ; Eisai Inc., Nutley, NJ, USA.
Reyderman L; Eisai Inc., Nutley, NJ, USA.
Kanekiyo M; Eisai Inc., Nutley, NJ, USA.
Koyama A; Eisai Inc., Nutley, NJ, USA.
Irizarry M; Eisai Inc., Nutley, NJ, USA.
Kramer LD; Eisai Inc., Nutley, NJ, USA.
Bateman RJ; The DIAN-TU, Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. .
Pokaż więcej
Źródło:
Alzheimer's research & therapy [Alzheimers Res Ther] 2022 Dec 21; Vol. 14 (1), pp. 191. Date of Electronic Publication: 2022 Dec 21.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Alzheimer Disease*/diagnostic imaging
Alzheimer Disease*/drug therapy
Humans ; Brain/diagnostic imaging ; Antibodies, Monoclonal, Humanized/therapeutic use ; Biomarkers ; Amyloidogenic Proteins ; Cognition ; Amyloid beta-Peptides
Czasopismo naukowe
Tytuł:
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.
Autorzy:
Dhadda S; Eisai Inc, Nutley, NJ, USA.
Kanekiyo M; Eisai Inc, Nutley, NJ, USA.
Li D; Eisai Inc, Nutley, NJ, USA.
Swanson CJ; Eisai Inc, Nutley, NJ, USA.
Irizarry M; Eisai Inc, Nutley, NJ, USA.
Berry S; Berry Consultants, LLC, Austin, TX, USA.
Kramer LD; Eisai Inc, Nutley, NJ, USA.
Berry DA; Berry Consultants, LLC, Austin, TX, USA. .; University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. .
Pokaż więcej
Źródło:
Alzheimer's research & therapy [Alzheimers Res Ther] 2022 Dec 09; Vol. 14 (1), pp. 182. Date of Electronic Publication: 2022 Dec 09.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Alzheimer Disease*/drug therapy
Humans ; Bayes Theorem ; Proof of Concept Study ; Research Design
Czasopismo naukowe
Tytuł:
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Autorzy:
Swanson CJ; Eisai Inc., Woodcliff Lake, NJ, USA.
Zhang Y; Eisai Inc., Woodcliff Lake, NJ, USA.
Dhadda S; Eisai Inc., Woodcliff Lake, NJ, USA.
Wang J; Eisai Inc., Woodcliff Lake, NJ, USA.
Kaplow J; Eisai Inc., Woodcliff Lake, NJ, USA.
Lai RYK; Eisai Ltd., Hatfield, UK.
Lannfelt L; BioArctic AB, Warfvinges väg 35, SE-112 51, Stockholm, Sweden.; Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden.
Bradley H; Eisai Inc., Woodcliff Lake, NJ, USA.
Rabe M; Eisai Inc., Woodcliff Lake, NJ, USA.
Koyama A; Eisai Inc., Woodcliff Lake, NJ, USA.
Reyderman L; Eisai Inc., Woodcliff Lake, NJ, USA.
Berry DA; Berry Consultants, LLC, Austin, TX, USA.
Berry S; Berry Consultants, LLC, Austin, TX, USA.
Gordon R; Eisai Ltd., Hatfield, UK.
Kramer LD; Eisai Inc., Woodcliff Lake, NJ, USA.
Cummings JL; Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA. .
Pokaż więcej
Źródło:
Alzheimer's research & therapy [Alzheimers Res Ther] 2021 Apr 17; Vol. 13 (1), pp. 80. Date of Electronic Publication: 2021 Apr 17.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Alzheimer Disease*/complications
Alzheimer Disease*/diagnostic imaging
Alzheimer Disease*/drug therapy
Amyloid beta-Peptides*
Bayes Theorem ; Brain ; Double-Blind Method ; Humans
Czasopismo naukowe
Tytuł:
Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy.
Autorzy:
Yamashita K; Central Research Laboratories, Sysmex Corporation, Kobe, Japan.
Miura M; Central Research Laboratories, Sysmex Corporation, Kobe, Japan.
Watanabe S; Central Research Laboratories, Sysmex Corporation, Kobe, Japan.
Ishiki K; Central Research Laboratories, Sysmex Corporation, Kobe, Japan.
Arimatsu Y; Business Incubation Division, Sysmex Corporation, Kobe, Japan.
Kawahira J; Business Incubation Division, Sysmex Corporation, Kobe, Japan.
Kubo T; Sysmex R&D Center Americas, Inc., Mundelein, IL, USA.
Sasaki K; Reagent Engineering Division, Sysmex Corporation, Kobe, Japan.
Arai T; Reagent Engineering Division, Sysmex Corporation, Kobe, Japan.
Hagino K; Business Incubation Division, Sysmex Corporation, Kobe, Japan.
Irino Y; Central Research Laboratories, Sysmex Corporation, Kobe, Japan.
Nagai K; Japan and Asia Clinical Development Department, Eisai Co., Ltd., Tokyo, Japan.
Verbel D; Biostatistics, Eisai Inc., Nutley, NJ, USA.
Koyama A; Translational Science, Eisai Inc., Nutley, NJ, USA.
Dhadda S; Biostatistics and Project Operations, Eisai Inc., Nutley, NJ, USA.
Niiro H; Medical Affairs Division, Sysmex Corporation, Kobe, Japan.
Iwanaga S; Central Research Laboratories, Sysmex Corporation, Kobe, Japan. .
Sato T; Central Research Laboratories, Sysmex Corporation, Kobe, Japan.
Yoshida T; Sysmex Corporation, Kobe, Japan.
Iwata A; Department of Neurology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan. .
Pokaż więcej
Źródło:
Alzheimer's research & therapy [Alzheimers Res Ther] 2022 Jun 23; Vol. 14 (1), pp. 86. Date of Electronic Publication: 2022 Jun 23.
Typ publikacji:
Journal Article
MeSH Terms:
Alzheimer Disease*/diagnostic imaging
Amyloidosis*
Aged ; Amyloid ; Amyloid beta-Peptides/cerebrospinal fluid ; Biomarkers/cerebrospinal fluid ; Female ; Humans ; Immunoassay ; Peptide Fragments/cerebrospinal fluid ; Positron-Emission Tomography ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Protocol for a single-arm, pilot trial of creatine monohydrate supplementation in patients with Alzheimer's disease.
Autorzy:
Taylor, Matthew K. (AUTHOR)
Burns, Jeffrey M. (AUTHOR)
Choi, In-Young (AUTHOR)
Herda, Trent J. (AUTHOR)
Lee, Phil (AUTHOR)
Smith, Aaron N. (AUTHOR)
Sullivan, Debra K. (AUTHOR)
Swerdlow, Russell H. (AUTHOR)
Wilkins, Heather M. (AUTHOR)
Pokaż więcej
Źródło:
Pilot & Feasibility Studies. 2/27/2024, Vol. 10 Issue 1, p1-10. 10p.
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies